# A trial of GLP-1 weight-loss drugs with cancer as the primary outcome

Source: https://onco.cc/ideas/idea-prev-glp1-cancer-prevention-rct/  
OnCo record `idea-prev-glp1-cancer-prevention-rct` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Obesity raises the risk of 13 cancers, and GLP-1 weight-loss drugs are already in routine use for diabetes and obesity. Observational data hint that they cut obesity-related cancers but confounding is severe, so a randomised trial in adults aged 50 to 70 with a BMI of 30 or more should make cancer the primary outcome.

## Summary

Observational data suggest GLP-1 receptor agonists reduce obesity-related cancer incidence, but confounding is severe. Propose an RCT, or prospective cancer adjudication embedded in ongoing cardiovascular outcome trials, with incident obesity-related cancer as the primary endpoint in adults aged 50-70 with BMI of 30 or more.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: GLP-1 receptor agonist therapy reduces incidence of obesity-related cancers by at least 20% over seven years.
- Rationale: Bariatric surgery reduces cancer incidence in cohort studies; pharmacological weight loss may reproduce this through insulin/IGF and inflammatory pathways.
- Proposed test: Run a 20,000-person RCT or a pooled analysis of cardiovascular outcome trials with prospective cancer adjudication.
- Maturity: early-clinical
- Actor: industry

## Sources

- Bottleneck evidence (Prevention we already have is not deployed): Islami et al., Proportion of cancer attributable to modifiable risk factors (CA 2018): https://doi.org/10.3322/caac.21440

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Endometrial cancer](https://onco.cc/cancers/endometrial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Chemoprevention & risk-reducing surgery](https://onco.cc/technologies/chemoprevention/), [GLP-1 receptor agonists and obesity-related cancer risk](https://onco.cc/technologies/glp1-agonists-cancer-risk/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- bottlenecks: [Prevention we already have is not deployed](https://onco.cc/bottlenecks/b-prevention-adoption/)
- key papers: [IARC verdict: excess body fat causes 13 cancers](https://onco.cc/key-papers/paper-body-fatness-iarc-nejm-2016/), [Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States](https://onco.cc/key-papers/paper-islami-ca-cancer-j-clin/)
- ideas: [GLP-1 receptor agonists as adjuvant weight-loss therapy in HR-positive breast cancer](https://onco.cc/ideas/idea-nl-glp1-adjuvant-hr-breast/), [Link bariatric and GLP-1 registries to cancer registries in every country that has both](https://onco.cc/ideas/idea-nl-bariatric-cancer-registry-linkage/)
- roadmaps: [Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers](https://onco.cc/roadmaps/prevention-roadmap/), [Diet, exercise and lifestyle roadmap: causes established → interventions that disappointed → exercise proven as treatment](https://onco.cc/roadmaps/nutrition-lifestyle-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-glp1-cancer-prevention-rct.json